ANI Pharmaceuticals Inc (FRA:BSFA)
€ 54 -1.5 (-2.7%) Market Cap: 1.15 Bil Enterprise Value: 1.62 Bil PE Ratio: 0 PB Ratio: 3.00 GF Score: 85/100

Q3 2024 ANI Pharmaceuticals Inc Earnings Call Transcript

Nov 08, 2024 / 01:00PM GMT
Release Date Price: €54.5 (+2.83%)
Operator

Good day, everyone and welcome to today's Ani Pharmaceuticals Inc third quarter, 2024 earnings results call. Please note that this call is being recorded. After the speaker's opening remarks there will be a question and answer session. If you would like to ask a question during this time, simply press the star and the number one on your telephone keypad. If you would like to withdraw your question, please press star two. It is now my pleasure to turn the conference over to Lisa Wilson, please go ahead.

Lisa Wilson ANI Pharmaceuticals Inc;Investor Relations

Thank you, Todd. Welcome to ANI Pharmaceuticals Q3, 2024 earnings results call. This is Lisa Wilson Investor Relations for ANI with me on today's call are Nikhil Lalwani, President and Chief Executive Officer, Stephen Carey, Chief Financial Officer, and Christopher Mutz, senior Vice President and head of ANI's rare disease business. You can also access the webcast of this call through the investors section of the ANI website at anipharmaceuticals.com. Before we get started, I would like to remind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot